Ms. Rebecca Greco reports

STAGEZERO LIFE SCIENCES, LTD. SPECIAL AND ANNUAL GENERAL MEETING CONFERENCE CALL

Stagezero Life Sciences Ltd. will host a conference call as part of its special and annual general meeting of shareholders on Wednesday June 7, 2023, so that all shareholders may follow along with the proceedings of the meeting.

Annual general and special meeting conference call

Event date:  Wednesday, June 7, 2023

Time:  2 p.m. ET

Conference call numbers

Canada/United States toll-free:  1-800-319-4610

Toronto toll:  1-416-915-3239

International toll:   1-604-638-5340

About Stagezero Life Sciences Ltd.

Stagezero Life Sciences is a vertically integrated health care company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and a unique telehealth program that provides clinical interventions to help patients reduce the risk of developing late-stage disease (AVRT).

The company's next-generation test, Aristotle, is the first ever mRNA multicancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.

Aristotle, as well as additional cancer diagnostics (ColonSentry, BreastSentry and the Prostate Health Index), are processed at the company's clinical laboratory, Stagezero Life Sciences Inc., a College of American Pathologists-accredited and Clinical Laboratory Improvement Amendments-certified high-complexity reference laboratory in Richmond, Va. In addition, the company offers multiple telehealth delivered clinical programs for risk stratification and cancer treatment under the guidance of experienced oncologists.